Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of the Booster Dose of Polio Vaccine With Different Primary Sequential Schedules in China

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Participants aged ≥48 months to ≤ 51 months from preliminary study (NCT03147560) with sequential immunization history by Sabin IPV and bOPV.~* Parent/legal acceptable representative is willing and able to understand the protocol requirements and provide informed consent.~* ≥ 14 days interval between the last vaccination.~* Body temperature ≤ 37.2℃.~Exclusion Criteria:~* Known acute illness, severe chronic disease, acute exacerbation of chronic disease and fever.~* Known allergy to any constituent of the vaccine.~* Had 4 doses vaccination record of polio vaccine.~* Known impairment of immunologic function, or receipt of immunosuppressive therapy or immunoglobulin .~* Received non-specific immunoglobulin within 1 month.~* An acute illness with fever (temperature ≥ 37.3℃) or any infectious diseases.~* Patients with a well-diagnosed history of thrombocytopenia or other coagulation disorders that may cause contraindications for injection.~* Any condition which, in the opinion of the investigator, would pose a health risk to the subject or interfere with the vaccine.

- Gender: ALL
- Minimum Age: 48 Months
- Maximum Age: 51 Months
- Healthy Volunteers: t

Study Arms:
- Group A(Sabin IPV+ bOPV+ bOPV+Sabin IPV) (Type: EXPERIMENTAL): Give the 4th doses of polio vaccine with Sabin IPV for participants in the Group 1 of preliminary study (NCT03147560).
- Group B(Sabin IPV+ Sabin IPV+ bOPV+bOPV) (Type: EXPERIMENTAL): Give the 4th doses of polio vaccine with bOPV for participants in the Group 2 of preliminary study (NCT03147560) after randomization.
- Group C(Sabin IPV+ Sabin IPV+ bOPV+Sabin IPV) (Type: EXPERIMENTAL): Give the 4th doses of polio vaccine with Sabin IPV for participants in the Group 2 of preliminary study (NCT03147560) after randomization.
- Group D(Sabin IPV+ Sabin IPV+ Sabin IPV+bOPV) (Type: EXPERIMENTAL): Give the 4th doses of polio vaccine with bOPV for participants in the Group 3 of preliminary study (NCT03147560) after randomization.
- Group E(Sabin IPV+ Sabin IPV+ Sabin IPV+Sabin IPV) (Type: EXPERIMENTAL): Give the 4th doses of polio vaccine with Sabin IPV for participants in the Group 3 of preliminary study (NCT03147560) after randomization.

Based on this trial design, predict the completion outcome and termination type (if applicable).